Latest Breaking News On - Raclons alzheimers vaccine shows clean safety profile in phase ii analysis - Page 1 : comparemela.com

While the trial was designed to test safety and not efficacy, patients treated with Araclon Biotech’s experimental ABvac40 vaccine saw a 38% drop in disease progression compared to placebo.

Jose terencioBoada roviraArtur plawgoGrifols groupElan pharmaceuticalsMini mental state examinationRepeatable batteryNeuropsychological statusTrial making testFast track designationRaclons alzheimers vaccine shows clean safety profile in phase ii analysis